108 related articles for article (PubMed ID: 20549338)
41. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
[TBL] [Abstract][Full Text] [Related]
42. HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
Ferretti G; Di Cosimo S; Giannarelli D; Carlini P; Papaldo P; Alimonti A; Fabi A; Mandalà M; Milella M; Ruggeri EM; Cognetti F
J Clin Oncol; 2004 Feb; 22(3):568-9. PubMed ID: 14752083
[No Abstract] [Full Text] [Related]
43. Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Popat S; Smith IE
J Natl Cancer Inst; 2005 Jun; 97(11):858; author reply 858-9. PubMed ID: 15928308
[No Abstract] [Full Text] [Related]
44. Implication of HER-2/neu overexpression for the efficacy of oral fluoropyrimidine-based adjuvant chemotherapy in the patients with estrogen receptor negative breast cancer after surgery.
Nio Y; Itakura M; Omori H; Koike M; Hashimoto K; Yano S; Toga T; Higami T
Anticancer Res; 2003; 23(1B):745-53. PubMed ID: 12680178
[TBL] [Abstract][Full Text] [Related]
45. Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression.
Tarantino P; Curigliano G
Breast Cancer Res Treat; 2021 Apr; 186(3):885-886. PubMed ID: 33634418
[No Abstract] [Full Text] [Related]
46. Where to with HER2?
Sledge GW
Clin Breast Cancer; 2010 Feb; 10(1):18. PubMed ID: 20133253
[No Abstract] [Full Text] [Related]
47. Many Women With the Most Common Form of Breast Cancer Can Skip Chemotherapy: Study finds that approximately 70% of patients with this form of the disease do not need adjuvant chemotherapy.
Cancer; 2018 Aug; 124(16):3281-2382. PubMed ID: 30141836
[No Abstract] [Full Text] [Related]
48. Two birds with one stone: octreotide treatment for acromegaly and breast cancer.
Chae YK; Hu MI; Katz RL; Chavez-MacGregor M; Haluska P; Meric-Bernstam F; Gonzalez-Angulo AM; Melhem-Bertrandt A
J Clin Oncol; 2013 Aug; 31(23):e398-400. PubMed ID: 23796991
[No Abstract] [Full Text] [Related]
49. The financial burden of using Oncotype Dx for patients with lymph node-negative and estrogen receptor-positive breast cancer in Australia.
Sakata S; Cronk M
Asia Pac J Clin Oncol; 2014 Mar; 10(1):94-5. PubMed ID: 23718901
[No Abstract] [Full Text] [Related]
50. Consuming a high-fat diet is associated with increased risk of certain types of BC.
Sieri S
J Natl Cancer Inst; 2014 May; 106(5):. PubMed ID: 24977271
[No Abstract] [Full Text] [Related]
51. Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer.
Anderson WF; Rosenberg PS; Katki HA
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777110
[No Abstract] [Full Text] [Related]
52. Chemotherapy for oestrogen-receptor-negative breast cancer.
Yerushalmi R; Gelmon K
Lancet; 2008 Jan; 371(9606):4-5. PubMed ID: 18177755
[No Abstract] [Full Text] [Related]
53. Aspirin intake may prevent metastasis in patients with triple-negative breast cancer.
Ararat E; Sahin I; Altundag K
Med Oncol; 2011 Dec; 28(4):1308-10. PubMed ID: 20668965
[No Abstract] [Full Text] [Related]
54. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.
Piccart MJ; Kalinsky K; Gray R; Barlow WE; Poncet C; Cardoso F; Winer E; Sparano J
Ann Oncol; 2021 Sep; 32(9):1077-1082. PubMed ID: 34082017
[No Abstract] [Full Text] [Related]
55. Quantitative measures of oestrogen receptor and ERBB2 expression.
Hayes DF
Lancet Oncol; 2007 Mar; 8(3):184-5. PubMed ID: 17329185
[No Abstract] [Full Text] [Related]
56. Adjuvant chemotherapy for breast cancer in older women.
Berry DA
Womens Health (Lond); 2009 Sep; 5(5):453-7. PubMed ID: 19702442
[No Abstract] [Full Text] [Related]
57. Polycystic ovary syndrome and breast cancer subtypes: a Mendelian randomization study.
Zhu T; Cui J; Goodarzi MO
Am J Obstet Gynecol; 2021 Jul; 225(1):99-101. PubMed ID: 33771497
[No Abstract] [Full Text] [Related]
58. Ten remarkable years.
Sledge GW
Clin Breast Cancer; 2010 Jun; 10(3):178. PubMed ID: 20497915
[No Abstract] [Full Text] [Related]
59. Evaluating an ER Degrader for Breast Cancer.
Cancer Discov; 2015 Jul; 5(7):OF15. PubMed ID: 25956960
[No Abstract] [Full Text] [Related]
60. Oestrogen and progesterone receptor dissociation and family history of breast cancer.
Lehrer S; Levine E; Savoretti P; Cropley J; Thung SN; Song HK; Mandell L; Shank B
Lancet; 1992 May; 339(8801):1108-9. PubMed ID: 1349117
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
